Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide + bortezomib + dexamethasone for newly diagnosed multiple myeloma with renal insufficiency (ChiCTR2100043748)
ChiCTR2100043748Phase 2Completed
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Mar 2021
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide in multiple myeloma (MM) and tubulointerstitial disease (TIN), sponsored by Beijing Chaoyang Hospital. Primary endpoint: Renal overall response rate at 3 months. Started Mar 2021; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)tubulointerstitial disease (TIN)
Beyond the preview
Go deeper on ChiCTR2100043748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043748.